Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as ...

Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the ...

Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for ...

The company is building a new facility in California, its third U.S.-based radioligand therapy production site, and expanding ...

Eli Lilly’s weekly insulin injection efsitora alfa secured two late-stage victories on Thursday in a potential blow to rival ...

A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO ...

Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive ...

Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage ...

Facing financial challenges, IN8bio is looking to preserve cash resources through a pipeline prioritization and layoffs at ...

BioMarin executives sought to calm an anxious investor base Wednesday with a public address and pledge to achieve a nearly 50 ...

With gene therapies by REGENXBIO and AbbVie, Adverum and others in mid- or late-stage trials, this therapeutic class could ...

Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial ...